Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems:Stocks w/Strong Earnings and High Tech. Rank -- Ignore unavailable to you. Want to Upgrade?

To: Margaret Mateer who wrote (56642)	8/19/1999 8:35:00 PM
From: kendall harmon	Read Replies (1) \| Respond to of 120523

UTHR--The next event that matters for UTHR is the ESC (European Society of Cardiology) meeting in Barcelona, August 28-Sept 1. Dr. Stuart Rich, who is one of the foremost experts in the world on pulmonary hypertension, will be giving the talk on UT-15, UTHR's lead product. What is important is to learn how this product compares to a less stable product put out by Glaxo Wellcome called Flolan. Flolan is currently on the market, but this new analog of a naturally occurring compound called prostacyclin put out by UTHR is supposed to be (1) more effective and (2) easier to use. If UT-15 is successful it could generate at least 250 million in annual sales. There are other UTHR"s products such as Beraprost for the treatment of peripheral vascular disease which could further enhance sales. But one thing at a time, Spain is where it is at for any UTHR holders at this point. (Personal note to the thread: yes, I was a College chemistry major.)

To: Margaret Mateer who wrote (56642)	8/20/1999 9:21:00 AM
From: Spartex	Respond to of 120523

Margaret thanks! I've also noticed that NOVL has also initiated a new share repurchase program. Seems like their employees will be getting more options to replace those they sold. Hmmmm, what's in it for me?! Presumably, company performance-- we'll see. ++++++++++++++++++++++++++++++++++++++++++++++ During the quarter, the company spent $57 million to repurchase 4 million shares of Novell common stock. On June 5, 1998, Novell's Board of Directors authorized the company to repurchase up to 10 percent, or approximately 35 million shares, of Novell common stock over 12 months. To date, the company has spent $448 million to purchase and retire 34,550,000 shares of common stock that were authorized for repurchase. Recent Board Actions On July 26, 1999, Novell's Board of Directors authorized up to $500 million for a share repurchase program through October 31, 2000, with the intent of offsetting the impact of exercised stock options and the effect of the Treasury method of accounting for outstanding stock options. The objective of the new plan is to maintain a fairly constant weighted average share count of approximately 350 million shares.